Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Pozycja w akcjach #4537
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Cena akcji
$27.18
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$3.38B
Zmiana (1 dzień)
-1.41%
Zmiana (1 rok)
197.05%
Kraj
US
Handel Tango Therapeutics, Inc. (TNGX)

Kategoria

Healthcare
EPS dla Tango Therapeutics, Inc. (TNGX)
EPS na dzień June 2026 TTM: $-0.85
Według najnowszych raportów finansowych i ceny akcji firmy Tango Therapeutics, Inc., obecny EPS (TTM) wynosi $-0.85. Na koniec roku 2023 firma miała EPS w wysokości $-1.08, spadek w porównaniu do do EPS z roku 2022, który wynosił $-1.23.
Historia EPS dla Tango Therapeutics, Inc. od 2019 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-0.85 -28.57%
2024 $-1.19 10.19%
2023 $-1.08 -12.20%
2022 $-1.23 30.85%
2021 $-0.94 -41.98%
2020 $-1.62 3.18%
2019 $-1.57 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -2,137.65%
US
$-7.98 838.82%
US
$-5.29 522.35%
AU
- -
CH
$27.74 -3,363.53%
NL